A Phase 1 interventional study of LOXO-305 and Omeprazole in Healthy Volunteers, sponsored by Loxo Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Period 1: Single oral dose of 200 milligram (mg) LOXO-305 (Fasted state) on Day 1 (Treatment A) * Period 2: Single oral dose of 200 mg LOXO-305 (Fed state) on Day 8 (Treatment B) * Period 3: Single oral dose of 40 mg Omeprazole (Fasted state) on Day 15 to 17 and single oral dose of 200 mg LOXO-305 + 40 mg Omeprazole (Fasted state) on Day 18 (Treatment C) A washout period of 7 days was maintained between each treatment period.
Drug: LOXO-305 · Drug: Omeprazole
* Period 1: Single oral dose of 200 mg LOXO-305 (Fed state) on Day 1 (Treatment B) * Period 2: Single oral dose of 200 mg LOXO-305 (Fasted state) on Day 8 (Treatment A) * Period 3: Single oral dose of 40 mg Omeprazole (Fasted state) on Day 15 to 17 and single oral dose of 200 mg LOXO-305 + 40 mg Omeprazole (Fasted state) on Day 18 (Treatment C) A washout period of 7 days was maintained between each treatment period.
Drug: LOXO-305 · Drug: Omeprazole
LOXO-305 orally.
Omeprazole Orally.
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305
PK: AUC(0-24) hours of LOXO-305 is reported. AUC(0-24) was calculated by the linear trapezoidal method.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post LOXO-305 dose
PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-305
PK: AUC(0-t) of LOXO-305 is reported. AUC(0-t) was calculated by linear trapezoidal method.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-305
PK: AUC(0-inf) of LOXO-305 is reported. AUC(0-inf) was calculated using the formula: AUC(0-inf) = AUC(0-t) + Ct/λZ; where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-305
PK: %AUCextrap of LOXO-305 is reported.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305
PK: Cmax of LOXO-305 is reported.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-305
PK: tmax of LOXO-305 is reported.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Apparent Terminal Elimination Half-life (t½) of LOXO-305
PK: t½ of LOXO-305 is reported.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
PK: Apparent Systemic Clearance (CL/F) of LOXO-305
PK: CL/F of LOXO-305 is reported.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Participants were randomized to 2 treatment sequences (ABC and BAC), with each sequence having 3 periods where participants were crossed over between the periods in each sequence. A washout period of 7 days was maintained between each treatment period.
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC |
|---|---|---|
| Started | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
PK: AUC(0-24) hours of LOXO-305 is reported. AUC(0-24) was calculated by the linear trapezoidal method.
| hour*nanograms per milliliter | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305 | 55100 ± 17.5 | 51900 ± 12.8 | 59900 ± 15.5 |
PK: AUC(0-t) of LOXO-305 is reported. AUC(0-t) was calculated by linear trapezoidal method.
| hour*nanograms per milliliter | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-305 | 89400 ± 17.8 | 85100 ± 19.3 | 99600 ± 17.1 |
PK: AUC(0-inf) of LOXO-305 is reported. AUC(0-inf) was calculated using the formula: AUC(0-inf) = AUC(0-t) + Ct/λZ; where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.
| hour*nanograms per milliliter | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-305 | 90200 ± 17.6 | 86100 ± 18.9 | 101000 ± 16.8 |
PK: %AUCextrap of LOXO-305 is reported.
| percentage of extrapolation | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-305 | 0.911 ± 27.2 | 1.12 ± 42.6 | 0.893 ± 34.5 |
PK: Cmax of LOXO-305 is reported.
| nanograms per milliliter | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 | 5450 ± 31.7 | 4340 ± 16.6 | 5490 ± 16.7 |
PK: tmax of LOXO-305 is reported.
| hours | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-305 | 2.50 (1.50 to 4.00) | 3.00 (1.00 to 4.00) | 2.25 (1.50 to 3.00) |
PK: t½ of LOXO-305 is reported.
| hours | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Apparent Terminal Elimination Half-life (t½) of LOXO-305 | 20.2 ± 4.24 | 21.5 ± 5.75 | 19.7 ± 2.87 |
PK: CL/F of LOXO-305 is reported.
| Liter per Hours (L/h) | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) |
|---|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of LOXO-305 | 2.22 ± 17.6 | 2.32 ± 18.9 | 1.99 ± 16.8 |
Collected over Day 1 up to Day 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: 200 mg LOXO-305 (Fasted) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Treatment B: 200 mg LOXO-305 (Fed) | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Treatment C: 40 mg Omeprazole (Fasted) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Event | Treatment A: 200 mg LOXO-305 (Fasted) | Treatment B: 200 mg LOXO-305 (Fed) | Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted) | Treatment C: 40 mg Omeprazole (Fasted) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/10 | 1/10 | 0/10 | 0/10 |
| VomitingGastrointestinal disorders | 0/10 | 1/10 | 0/10 | 0/10 |
| HeadacheNervous system disorders | 0/10 | 1/10 | 0/10 | 0/10 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC | Total |
|---|---|---|---|
| Mean | 43.2 ± 10.66 | 35.2 ± 4.87 | 39.2 ± 8.88 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 4 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 4 | 4 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Treatment Sequence 1: ABC | Treatment Sequence 2: BAC | Total |
|---|---|---|---|
| United States | 5 | 5 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Mar 2020, 1 month.
Results were first posted in Jan 2025, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib